Aclaris Q4 net loss $19.8M; cash $151.4M; ATI-052 POC trials underway

Aclaris Therapeutics, Inc.

2025-FY EPS reported -$0.53 revenue$7,826,000

Net loss of $19.8M in Q4 2025 vs $96.6M in Q4 2024; full year net loss $64.9M vs $132.1M.
Total revenue $1.3M in Q4 2025 vs $9.2M prior year; decrease due to 2024 Lilly milestone.
Cash, equivalents and marketable securities $151.4M as of Dec 31, 2025; cash runway into H2 2028.
Interim Phase 1a data for anti-TSLP/IL-4Rα bispecific ATI-052 support rapid advancement; Phase 1b POC trials in AD and asthma initiated.
IND filing for lead ITK inhibitor ATI-9494 expected H2 2026; ATI-2138 showed hair regrowth in alopecia model.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.